# Stem cell therapy for autoimmune disease Living mesenchymal stromal cells (MSC) or regulatory T cells (Treg) are infused to re-tolerise the immune system in autoimmune and inflammatory disease — an approved-asset class led by Mesoblast's Ryoncil for steroid-refractory GVHD and TiGenix's Alofisel for Crohn's fistula, with a deeper engineered-Treg pipeline for lupus, arthritis and aplastic anemia. Source: https://en.bioecon.ru/technology/stem-cell-therapy-autoimmune/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: ATMP Regulation (EC No 1394/2007) + FDA cell-therapy guidance | OECD: Bio-pharma | Regulator: FDA (USA), EMA (European Union), NMPA (China)] Stem cell therapy for autoimmune disease uses living cells — mesenchymal stromal cells (MSC) or regulatory T cells (Treg) — to re-tolerise rather than suppress the immune system, addressing lupus, Crohn's, arthritis, GVHD and aplastic anaemia. Mesoblast's Ryoncil (remestemcel-L) saw the FDA accept its Biologics License Application for paediatric steroid-refractory acute graft-versus-host disease; TiGenix (a Takeda company) provides Alofisel (darvadstrocel) for Crohn's disease perianal fistulas; Cellenkos received FDA clearance for a Phase 2 trial of CK0801 (allogeneic cord-blood Treg) in aplastic anaemia; Sonoma Biotherapeutics is advancing an engineered-Treg pipeline in autoimmune disease; and GentiBio presented preclinical data for GNTI-122, an autologous antigen-specific engineered Treg. The key directions of stem cell therapy for autoimmune disease are: 1. **Mesenchymal stromal cell therapy (MSC):** allogeneic MSC immunomodulation for inflammatory disease — Mesoblast (remestemcel-L/Ryoncil, steroid-refractory acute GVHD), TiGenix (darvadstrocel/Alofisel, Crohn's perianal fistula). 2. **Regulatory T-cell therapy (Treg):** polyclonal or antigen-specific Treg infusion to restore tolerance — Cellenkos (CK0801 cord-blood Treg, aplastic anaemia), Sonoma Biotherapeutics (engineered Treg), GentiBio (GNTI-122 antigen-specific Treg). 3. **Haematopoietic stem-cell reset (HSCT):** autologous HSCT for severe refractory autoimmune disease (lupus, MS), a clinical-procedure rather than product-led approach. 4. **Allogeneic off-the-shelf manufacturing (Allogeneic Manufacturing):** donor-derived MSC and Treg banking that supports repeat-dose, inventory-managed cell therapy. ### Sectoral value chain ``` [donor MSC / cord-blood Treg / patient Treg] ──> [ex vivo activation, engineering & expansion] ──> [cryopreserved cell product] │ (conditioning as needed) │ ▼ [immune tolerance restored] <─── [cell infusion + immune monitoring] <─────┘ ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **Cell Source & Donor** | donor MSC, cord-blood Treg, or autologous Treg, with screening and HLA considerations | **In:** donor/patient, apheresis.
**Out:** starting cells. | | **Engineering & Expansion** | ex vivo MSC expansion or Treg activation, optional antigen-specific TCR engineering | **In:** cells, cytokines.
**Out:** therapeutic cell. | | **GMP Manufacture & Banking** | allogeneic cell bank, fill-finish, cryopreservation | **In:** expanded cells.
**Out:** banked doses. | | **Patient Conditioning** | minimal conditioning for MSC; lymphodepletion/specific conditioning for some Treg | **In:** patient, regimen.
**Out:** prepared host. | | **Infusion & Monitoring** | cell infusion and immune/tolerance monitoring | **In:** product, supportive care.
**Out:** response. | | **Follow-up & PV** | long-term tolerance durability, safety and pharmacovigilance | **In:** follow-up data.
**Out:** safety record. | Cross-cutting technologies of the sector: - **MSC immunomodulation (MSC):** allogeneic MSC suppress inflammation via IDO, PGE2 and T-cell modulation, enabling off-the-shelf use across HLA barriers (Mesoblast, TiGenix). - **Treg stability and specificity (Treg):** maintaining FOXP3 expression and engineering antigen-specific TCRs so the infused Treg homes to the diseased tissue (Cellenkos, Sonoma, GentiBio). - **Allogeneic off-the-shelf banking (Allogeneic Manufacturing):** donor-derived MSC/Treg banked as inventory distinguishes this class from autologous cell therapy. --- ## US The US hosts Mesoblast (the MSC commercial leader), Cellenkos, Sonoma Biotherapeutics and GentiBio, and the FDA has accepted the lead MSC asset's BLA. ### Mesoblast, Cellenkos, Sonoma, GentiBio, FDA - **Mesoblast:** the FDA accepted its Biologics License Application for Ryoncil (remestemcel-L) in children with steroid-refractory acute graft-versus-host disease, the lead allogeneic-MSC regulatory asset; remestemcel-L is the most-studied MSC in inflammatory disease. - **Cellenkos:** received FDA clearance to initiate a Phase 2 clinical trial of CK0801, an allogeneic cord-blood-derived Treg, for aplastic anaemia, extending Treg therapy beyond oncology into autoimmune haematology. - **Sonoma Biotherapeutics:** a clinical-stage biotechnology company advancing an engineered-Treg pipeline for autoimmune disease, presenting data at the 2025 ACR meeting. - **GentiBio:** presented preclinical data for GNTI-122, its autologous antigen-specific engineered Treg lead, an approach designed to restore tolerance with tissue-restricted specificity. - **FDA framework:** MSC and Treg products are reviewed as advanced therapy biologics with cell-therapy-specific CMC, potency (often IDO for MSC) and long-term follow-up expectations. --- ## CN China runs an active academic-MSC autoimmune programme, with MSC clinical use in lupus and other autoimmune diseases, though it is more research- than product-led. ### academic MSC, lupus, NMPA - **Academic MSC in lupus:** Chinese centres have published extensively on MSC immunosuppression in systemic lupus erythematosus (e.g. effects on dendritic cells), but enrichment returned academic literature rather than a source-confirmed commercial MSC/Treg product, so the CN block is treated qualitatively. - **NMPA framework:** cell-therapy products are reviewed under the NMPA biologics framework; several MSC products are in domestic clinical use, but a dominant branded autoimmune MSC/Treg has not emerged. - **Autoimmune burden:** China's large systemic-autoimmune disease burden underpins sustained clinical interest in MSC and Treg tolerance therapy. --- ## EU Europe contributed the EU-approved MSC product Alofisel (TiGenix/Takeda) and the EMA's central ATMP authorisation route. ### TiGenix, Takeda, EMA, ATMP - **TiGenix (Spain, a Takeda company):** its Alofisel (darvadstrocel) is an EU-approved allogeneic MSC for complex perianal fistulas in adult Crohn's disease, and Takeda provides periodic updates on the programme as the EU's lead commercial autoimmune-MSC asset. - **EMA framework:** stem-cell products are advanced therapy medicinal products centrally authorised by the European Medicines Agency under Regulation (EC) No 1394/2007, with the hospital-exemption carve-out used cautiously for autologous products. - **European CDMO:** European cell-therapy CDMOs support GMP MSC expansion and cryopreservation, underpinning the allogeneic-bank model. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Mesoblast** | 🇺🇸 USA | *Ryoncil (remestemcel-L)* | Allogeneic MSC, SR-aGVHD | commercial | | **TiGenix** | 🇪🇸 Spain | *Alofisel (darvadstrocel)* | Allogeneic MSC, Crohn's fistula | commercial | | **Cellenkos** | 🇺🇸 USA | *CK0801 cord-blood Treg* | Allogeneic Treg, aplastic anaemia | operating | | **Sonoma Biotherapeutics** | 🇺🇸 USA | *engineered Treg pipeline* | Treg, autoimmune | operating | | **GentiBio** | 🇺🇸 USA | *GNTI-122 antigen-specific Treg* | Autologous engineered Treg | operating | --- ## Tech stack and innovations The stack pairs MSC or Treg cell sourcing with ex vivo expansion (and Treg engineering), allogeneic GMP banking, and immune-tolerance monitoring. 1. **Mesenchymal stromal cell therapy (MSC):** - Mesoblast's Ryoncil (remestemcel-L) had its BLA accepted for paediatric steroid-refractory acute GVHD, and TiGenix's Alofisel (darvadstrocel) is EU-approved for Crohn's perianal fistula — the two lead commercial autoimmune/inflammatory MSC assets. - Allogeneic MSC act via IDO/PGE2 immunomodulation across HLA barriers, enabling off-the-shelf use. 2. **Regulatory T-cell therapy (Treg):** - Cellenkos's CK0801 (allogeneic cord-blood Treg) entered Phase 2 in aplastic anaemia; Sonoma Biotherapeutics is clinical-stage in engineered Treg for autoimmune disease, and GentiBio presented preclinical data for GNTI-122, an antigen-specific engineered Treg. - Maintaining FOXP3 stability and engineering tissue-specific TCRs is what converts polyclonal Treg into disease-targeted tolerance therapy. 3. **Allogeneic manufacturing (Allogeneic Manufacturing):** - Donor-derived MSC and cord-blood Treg are banked as inventory, a structural shift from autologous cell therapy toward repeat-dose off-the-shelf cell drugs. --- ## Value chains and production pipelines ### Industrial pipeline of an autoimmune MSC/Treg product (ATMP Regulation) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. Cell source & donor │ ───> │ 2. Engineering & │ └───────────────────────────┘ │ expansion │ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. Patient conditioning │ <─── │ 3. GMP manufacture & │ │ │ │ banking │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. Infusion & monitoring │ ───> │ 6. Follow-up & PV │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: Cell source and donor Starting cells are sourced — donor bone-marrow/umbilical-cord MSC (Mesoblast, TiGenix), cord-blood Treg (Cellenkos), or autologous patient Treg (GentiBio) — with donor screening and HLA matching considered per product. #### Stage 2: Engineering and expansion MSC are expanded to therapeutic dose in culture; Treg are activated and expanded, and where antigen-specific, engineered with a tissue-homing TCR or CAR (Sonoma, GentiBio) before release testing. #### Stage 3: GMP manufacture and banking Allogeneic MSC and Treg are fill-finished, cryopreserved and banked as inventory under GMP, supporting off-the-shelf repeat-dose use; potency assays (e.g. IDO for MSC, FOXP3 for Treg) are the central release challenge. #### Stage 4: Patient conditioning MSC require minimal conditioning; some Treg protocols use low-dose lymphodepletion or IL-2 support to favour in-vivo Treg expansion and persistence. #### Stage 5: Infusion and monitoring The cell product is infused and the patient is monitored for tolerance induction (disease response, biomarker shifts) and acute infusion reactions. #### Stage 6: Follow-up and pharmacovigilance Long-term follow-up tracks durability of tolerance, need for repeat dosing, and safety (including any loss of tolerance or ectopic tissue effects), feeding the pharmacovigilance record for this still-young autoimmune cell-therapy class.